文献速递心力衰竭与心肌病

骨形态发生蛋白9减轻心力衰竭心脏纤维化并改善心功能

Bone Morphogenetic Protein 9 Reduces Cardiac Fibrosis and Improves Cardiac Function in Heart Failure.
PubMed 文献 · Circulation · 2018-01-01

研究探讨BMP9在心力衰竭中的作用,发现心衰患者循环和左心室BMP9表达升高,由心脏成纤维细胞表达。BMP9通过激活Smad1抑制I型胶原合成,BMP9缺失加重小鼠压力负荷后纤维化和心功能障碍,而重组BMP9或中和内皮糖蛋白可减轻纤维化并改善心功能。

要点

  • BMP9通过Smad1信号抑制心脏成纤维细胞I型胶原合成,减轻纤维化。
  • BMP9缺失加重压力负荷诱导的心肌纤维化和左室功能障碍。
  • 重组BMP9或中和内皮糖蛋白可改善心衰小鼠心功能,具治疗潜力。

核心结论

  • BMP9是压力负荷所致心脏纤维化的内源性抑制剂,重组BMP9或干扰内皮糖蛋白活性可促进BMP9活性并限制心衰纤维化。

研究设计与样本

  • 研究检测人心衰心脏成纤维细胞和心衰患者中BMP9表达与信号,并使用横向主动脉缩窄诱导的小鼠心衰模型评估BMP9信号对心脏重构的功能影响。

主要发现

  • 心衰患者循环和左心室BMP9表达升高,且由心脏成纤维细胞表达。
  • 重组人BMP9及小干扰RNA方法显示BMP9减弱人心脏成纤维细胞I型胶原合成。
  • BMP9-/-小鼠横向主动脉缩窄后心脏纤维化加重、左室功能受损,左室磷酸化Smad3水平升高而非磷酸化Smad1。
  • 野生型小鼠横向主动脉缩窄后给予重组BMP9,与溶剂对照相比,限制心脏纤维化进展、改善左室功能、增强心肌毛细血管密度并升高左室磷酸化Smad1而非磷酸化Smad3水平。
  • 在人心脏成纤维细胞或野生型小鼠横向主动脉缩窄诱导心衰中中和内皮糖蛋白活性,限制胶原产生、增加BMP9蛋白水平并升高磷酸化Smad1而非磷酸化Smad3水平。

临床怎么用

  • BMP9信号通路可能作为心力衰竭抗纤维化治疗的新靶点,重组BMP9或靶向内皮糖蛋白或可成为潜在治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Heart failure is a growing cause of morbidity and mortality worldwide. Transforming growth factor beta (TGF-β1) promotes cardiac fibrosis, but also activates counterregulatory pathways that serve to regulate TGF-β1 activity in heart failure. Bone morphogenetic protein 9 (BMP9) is a member of the TGFβ family of cytokines and signals via the downstream effector protein Smad1. Endoglin is a TGFβ coreceptor that promotes TGF-β1 signaling via Smad3 and binds BMP9 with high affinity. We hypothesized that BMP9 limits cardiac fibrosis by activating Smad1 and attenuating Smad3, and, furthermore, that neutralizing endoglin activity promotes BMP9 activity. METHODS: We examined BMP9 expression and signaling in human cardiac fibroblasts and human subjects with heart failure. We used the transverse aortic constriction-induced model of heart failure to evaluate the functional effect of BMP9 signaling on cardiac remodeling. RESULTS: BMP9 expression is increased in the circulation and left ventricle (LV) of human subjects with heart failure and is expressed by cardiac fibroblasts. Next, we observed that BMP9 attenuates type I collagen synthesis in human cardiac fibroblasts using recombinant human BMP9 and a small interfering RNA approach. In BMP9-/- mice subjected to transverse aortic constriction, loss of BMP9 activity promotes cardiac fibrosis, impairs LV function, and increases LV levels of phosphorylated Smad3 (pSmad3), not pSmad1. In contrast, treatment of wild-type mice subjected to transverse aortic constriction with recombinant BMP9 limits progression of cardiac fibrosis, improves LV function, enhances myocardial capillary density, and increases LV levels of pSmad1, not pSmad3 in comparison with vehicle-treated controls. Because endoglin binds BMP9 with high affinity, we explored the effect of reduced endoglin activity on BMP9 activity. Neutralizing endoglin activity in human cardiac fibroblasts or in wild-type mice subjected to transverse aortic constriction-induced heart failure limits collagen production, increases BMP9 protein levels, and increases levels of pSmad1, not pSmad3. CONCLUSIONS: Our results identify a novel functional role for BMP9 as an endogenous inhibitor of cardiac fibrosis attributable to LV pressure overload and further show that treatment with either recombinant BMP9 or disruption of endoglin activity promotes BMP9 activity and limits cardiac fibrosis in heart failure, thereby providing potentially novel therapeutic approaches for patients with heart failure.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Morine KJ, Qiao X, York S, et al. Bone Morphogenetic Protein 9 Reduces Cardiac Fibrosis and Improves Cardiac Function in Heart Failure. Circulation. 2018. PMID: 29487140. doi:10.1161/CIRCULATIONAHA.117.031635

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。